second-line systemic therapy

Phase 3Small molecule

second-line systemic therapy is one of 37 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerRecruiting

Non-Small Cell Lung CancerPhase 3

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

1 2

Carboplatin/paclitaxel

AstraZeneca

Phase 3

3 3

Consolidative Therapy

SSun Yat-sen University

Phase 3

2 4

second-line systemic therapy

SSun Yat-sen University

Phase 3

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 9

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Systemic Therapy

NCT06592612

Q3 2027

Phase 3Recruiting

Non-Small Cell Lung Cancer

NCT06523673

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT06523673·104 enrolled

Systemic Therapy1 trial

Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT06592612·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for second-line systemic therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — second-line systemic therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for second-line systemic therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSun Yat-sen University

second-line systemic therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Systemic Therapy1 trial

References

Drug Info

Quick Facts

Related News